These drugs are known to cause extreme nausea, vomiting, diarrhea, and gastroparesis
Of the ZEPBOUND-treated patients, 2.8% and 2.7% developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors, respectively, and 0.8% and 0.1% developed neutralizing antibodies against native GIP or GLP-1, respectively
Premature graying is often linked to high levels of oxidative stress within the melanocytes (the cells responsible for hair pigment)
Patients are paying attention because the magnitude of change suggests something different may be happening metabolically
Key results (Phase 3): In a 68-week Phase 3a trial published in The New England Journal of Medicine , cagrilintidesemaglutide (CagriSema) produced large mean weight loss (reported as ~22.7% at 68 weeks in the main efficacy analysis)
for semaglutide 2.4mg (Wegovy), reassessment at 6 months (NICE TA875)